CD274 and breast cancer: The epitopes and binding modes of the FDA-approved anti-PD-L1 antibodies can be references for the development of other antibodies in future and the BC, CC′, C′C′′, and FG loops of PD-L1 should provide key interactions for the development of improved anti-PD-L1 therapeutics including next-generation therapeutic antibodies and small-molecule modulators.